501 related articles for article (PubMed ID: 35088108)
21. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose.
Doyno C; Sobieraj DM; Baker WL
Clin Toxicol (Phila); 2021 Jan; 59(1):12-23. PubMed ID: 32960100
[TBL] [Abstract][Full Text] [Related]
22. COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.
de Barros CM; Almeida CAF; Pereira B; Costa KCM; Pinheiro FA; Maia LDB; Trindade CM; Garcia RCT; Torres LH; Diwan S; Boralli VB
Pain Physician; 2020 Aug; 23(4S):S351-S366. PubMed ID: 32942793
[TBL] [Abstract][Full Text] [Related]
23. Impact of repurposed drugs on the symptomatic COVID-19 patients.
Hussain I; Hussain A; Alajmi MF; Rehman MT; Amir S
J Infect Public Health; 2021 Jan; 14(1):24-38. PubMed ID: 33341481
[TBL] [Abstract][Full Text] [Related]
24. An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine.
Dragojevic Simic V; Miljkovic M; Stamenkovic D; Vekic B; Ratkovic N; Simic R; Rancic N
Int J Clin Pract; 2021 Mar; 75(3):e13825. PubMed ID: 33156564
[TBL] [Abstract][Full Text] [Related]
25. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
26. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Zequn Z; Yujia W; Dingding Q; Jiangfang L
Eur J Pharmacol; 2021 Feb; 893():173813. PubMed ID: 33345848
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study.
Liu X; Chen H; Shang Y; Zhu H; Chen G; Chen Y; Liu S; Zhou Y; Huang M; Hong Z; Xia J
Trials; 2020 Jul; 21(1):622. PubMed ID: 32641091
[TBL] [Abstract][Full Text] [Related]
28. A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial.
Abayomi A; Osibogun A; Ezechi O; Wright K; Ola B; Ojo O; Kuyinu Y; Zamba E; Abdur-Razzaq H; Erinoso OA; Anya SE
Trials; 2021 Dec; 22(1):869. PubMed ID: 34863267
[TBL] [Abstract][Full Text] [Related]
29. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
[TBL] [Abstract][Full Text] [Related]
30. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
[TBL] [Abstract][Full Text] [Related]
31. Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs.
Michaud V; Dow P; Al Rihani SB; Deodhar M; Arwood M; Cicali B; Turgeon J
Clin Transl Sci; 2021 Jan; 14(1):20-28. PubMed ID: 32888379
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
[TBL] [Abstract][Full Text] [Related]
33. Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs.
Rodgers F; Pepperrell T; Keestra S; Pilkington V
Trials; 2021 Jan; 22(1):59. PubMed ID: 33451350
[TBL] [Abstract][Full Text] [Related]
34. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
mBio; 2020 May; 11(3):. PubMed ID: 32444382
[TBL] [Abstract][Full Text] [Related]
35. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
36. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
[TBL] [Abstract][Full Text] [Related]
37. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.
Meriglier E; Rivoisy C; Hessamfar M; Bernard N; Aureau I; Lapoirie J; Contis A; Sacher F; Sacristan B; Lahouati M; Pedeboscq S; Vandenhende MA; Bouchet S; Bonnet F
J Antimicrob Chemother; 2021 Jan; 76(2):482-486. PubMed ID: 33221868
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
39. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F; Peiffer-Smadja N; Poissy J; Bouscambert-Duchamp M; Belhadi D; Diallo A; Delmas C; Saillard J; Dechanet A; Mercier N; Dupont A; Alfaiate T; Lescure FX; Raffi F; Goehringer F; Kimmoun A; Jaureguiberry S; Reignier J; Nseir S; Danion F; Clere-Jehl R; Bouiller K; Navellou JC; Tolsma V; Cabié A; Dubost C; Courjon J; Leroy S; Mootien J; Gaci R; Mourvillier B; Faure E; Pourcher V; Gallien S; Launay O; Lacombe K; Lanoix JP; Makinson A; Martin-Blondel G; Bouadma L; Botelho-Nevers E; Gagneux-Brunon A; Epaulard O; Piroth L; Wallet F; Richard JC; Reuter J; Staub T; Lina B; Noret M; Andrejak C; Lê MP; Peytavin G; Hites M; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Clin Microbiol Infect; 2021 Dec; 27(12):1826-1837. PubMed ID: 34048876
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review.
Qomara WF; Primanissa DN; Amalia SH; Purwadi FV; Zakiyah N
Int J Gen Med; 2021; 14():8557-8571. PubMed ID: 34849001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
